2-Picolinic Acid

2-Picolinic Acid

SCHEMBL2168036

O=C(O)c1ccccn1.[Mn]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.95
L3MBTL1 Q9Y468 2/20 0.95
NAPRT Q6XQN6 1/20 0.95
P4HTM Q9NXG6 1/20 0.95
CES2 O00748 1/20 0.67
CES1 P23141 1/20 0.67
KMT2A Q03164 2/20 0.63
ALDH1A1 P00352 2/20 0.61
GSK3B P49841 1/20 0.55
KDM4E B2RXH2 4/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MAPT P10636 2/20 0.53
PKM P14618 2/20 0.53
TDP1 Q9NUW8 2/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ACMSD Q8TDX5 1/20 0.52
PTGS2 P35354 1/20 0.50
CTNNB1 P35222 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL29368665 0.98
2-Picolinic Acid SCHEMBL36055 0.98
2-Picolinic Acid SCHEMBL28737810 0.98 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL7457912 0.98 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL674837 0.98 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL5667302 0.95 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL5058102 0.95 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL1462616 0.95 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL20721125 0.95 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL22835776 0.95 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240075043-A1 IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS Red Mountain Med Spa, LLC (US) 2024-03-07 US claimed
US-20220249505-A1 APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF RED MOUNTAIN HOLDINGS, LLC (US) 2022-08-11 US claimed
US-20210275536-A1 APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF RED MOUNTAIN HOLDINGS, LLC (US) 2021-09-09 US claimed
CN-105885691-B A kind of high-wearing feature wood wax oil and preparation method thereof 东莞市楚丰园环保科技有限公司 2018-05-08 CN claimed
US-9877939-B2 Composition and methods for the production of S-adenosylmethionine within the body FAST BALANCE, LLC (US) 2018-01-30 US claimed
CN-105885691-A High-wear-resistance wood wax oil and preparation method thereof 董学明 2016-08-24 CN claimed
US-20140235569-A1 COMPOSITION AND METHODS FOR THE PRODUCTION OF S-ADENOSYLMETHIONINE WITHIN THE BODY FAST BALANCE, INC. (US) 2014-08-21 US claimed
CN-103458876-A Galenical compositions suitable for administration to non-human animals, uses thereof and related methods VETALIS SARL 2013-12-18 CN claimed
EP-1411965-A4 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION NOVACTYL INC (US) 2006-01-11 EP claimed
US-20040105894-A1 Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions GUPTA SHYAM K (US) 2004-06-03 US claimed
EP-1411965-A1 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION Novactyl, Inc. (US) 2004-04-28 EP claimed
WO-2003006044-A1 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION NOVACTYL, INC. (US) 2003-01-23 WO claimed
US-20020037908-A1 Methods and compositions for controlling protein assembly or aggregation NOVACTYL, INC. 2002-03-28 US claimed
US-RE33988-E Dietary supplementation with essential metal picolinates The United States of America as repesented by the Secretary of Agriculture (US) 1992-07-07 US claimed
US-20260125422-A1 POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE NOVMETAPHARMA CO., LTD. (KR) 2026-05-07 US disclosed
US-12534496-B2 Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease NOVMETAPHARMA CO., LTD. (KR) 2026-01-27 US disclosed
WO-2025243087-A2 COMPOSITIONS, METHODS OF USING SAME, AND KITS COMPRISING SAME ATHLETIC GREENS INTERNATIONAL, INC. (KY) 2025-11-27 WO disclosed
EP-0514451-B1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS LIFESCIENCE CORP (US) 1997-01-15 EP disclosed
EP-0514451-A1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. UNIV TEXAS (US) 1992-11-25 EP disclosed
WO-1991011117-A2 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037908-A1 Methods and compositions for controlling protein assembly or aggregation PSEN1, PSEN2, PRNP LMNA 1073/4885L3MBTL1 4530/4885NAPRT 1920/4885
US-20140235569-A1 COMPOSITION AND METHODS FOR THE PRODUCTION OF S-ADENOSYLMETHIONINE WITHIN THE BODY BHMT2, BHMT, AHCY LMNA 2170/4885L3MBTL1 924/4885NAPRT 1184/4885
US-12534496-B2 Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease CRH, GHRHR, CRHBP LMNA 3149/4885L3MBTL1 2295/4885NAPRT 1142/4885
US-20260125422-A1 POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE CRH, PTMS, TRHR LMNA 3260/4885L3MBTL1 4007/4885NAPRT 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.